logo
We're Heading Toward A COVID Surge — Here's When It's Predicted To Peak

We're Heading Toward A COVID Surge — Here's When It's Predicted To Peak

Yahoo2 days ago
Those sniffles likely aren't a summer cold; COVID-19 is everywhere right now.
And things are expected to get worse before they get better. Some experts predict virus rates will continue to rise as we ride out this summer infection surge.
Jay Weiland, an infectious disease modeler, shared on social media that he predicts the summer COVID-19 wave will hit a peak in early September. So, now's the time to follow COVID prevention strategies such as wearing a mask in crowded spaces and washing your hands well.
Related:
Jenn Dowd, a professor of demography and population health at the University of Oxford in England, referenced Weiland's prediction model in her Substack newsletter, Data for Health, alongwith recent data from the Centers for Disease Control and Prevention that shows COVID infections rising in all but five states. 'Since the data are lagging by a week, it's likely levels are already higher, with a predicted peak in early September, just in time for back-to-school,' Dowd wrote in her newsletter.
This prediction should be taken with a grain of salt, though, experts say. COVID has proven to be anything but predictable over the last five-plus years.
'One thing to know is that a September peak is a best guess based on current trends, but we can't know for sure how big or long-lasting the current upswing in cases will be until we are on the other side of it,' Dowd told HuffPost via email.
COVID levels are lower than last summer, thankfully, according to wastewater data and hospitalization levels, 'but, back-to-school could pour fuel on the fire of any viral spread, so we'll get a better picture in the next few weeks,' Dowd added.
The models that are used to predict COVID peaks are an imperfect tool, but still contain valuable information, added Jessica Malaty Rivera, an infectious disease epidemiologist.
'If we look at the past, we've always had a summer wave [and] we've always also had a back-to-school flu season wave. So it's no surprise that they're cross-referencing both the historical incidence of COVID and what we're seeing in wastewater to say it's pretty likely that this many people probably have COVID right now, or may likely get COVID right now, because this many people are shedding the virus,' added Malaty Rivera.
But, Malaty Rivera said that wastewater data is only accurate to a certain extent.
'You can't always say that the presence of virus [in wastewater] is infectious virus,' she explained.
Wastewater data can't distinguish between active virus and non-infectious virus fragments from someone who was infected months ago, Malaty Rivera explained. (Just like how, early in the COVID pandemic, PCR tests could come back positive for months after someone recovered from a COVID-19 infection, she noted).
Related:
'And so the presence of COVID-19 [in wastewater] is not necessarily the presence of active virus. It could be a virus from people who were sick weeks ago or months ago who are still shedding virus, but it's not an infectious virus,' she added.
That being said, we are in a COVID surge right now and we should expect another bump as kids head back to school in September and as folks return from summer vacations, said Malaty Rivera.
'The fall, back to school, return from vacation, has always historically shown an uptick in respiratory illnesses, and COVID is not exclusive to that. COVID is now part of our annual cadence,' she said. 'And so the summer surge is no surprise, and to expect another bump is also completely based on evidence.'
If you do get sick during the summer COVID wave, here's what you should do:
If you get infected with COVID, the CDC's recommendations say you should stay home when you're sick and isolate from other people in your home. The CDC guidance goes on to say you can exit isolation once you're fever-free and your symptoms are improving or resolving for at least 24 hours.
At this point, you can return to your daily life, but should take additional steps to protect others, such as wearing a mask, staying away from other people, and washing your hands frequently for five extra days.
Malaty Rivera said you should take this one step further because 'resolving symptoms' is completely subjective, she noted. What's 'resolving' for one person could mean being very sick for another.
'And no fever... fever is not the only indicator... for infectiousness to others,' she added.
'Based on the evidence, if you are testing positive on a rapid antigen test, that means that you are likely infectious to others. If you are infectious to others, that means you should be isolating from other people and wearing a mask in indoor settings if you're forced to be in indoor settings with other people,' she said.
Related:
If you need fresh air, it's OK to go outside without a mask, but you shouldn't be close to other people, said Malaty Rivera.
'I don't think people should be unmasked in places with other people unless they are testing negative on an antigen test,' she said.
If you are sick, you can also check with your doctor to see if you're eligible for Paxlovid, which is an anti-viral COVID medication, Malaty Rivera said.
There are things you can do to prevent a COVID infection, too.
'If you didn't get an updated COVID vaccine in the past year, it might be a good time to get one, especially before any changes in eligibility come into effect,' said Dowd.
If you are over 65 or immunocompromised, you're eligible for another COVID shot, she added, so long as you're six months out from your last dose.
'But, besides protection from vaccines, when there is more COVID around, it's a good time to ramp up our trusty precautions that work for most respiratory viruses,' Dowd said.
Related:
'This includes paying attention to ventilation when socializing (such as being outside or opening doors and windows [and] using HEPA filters), staying home when sick and masking strategically in higher-risk situations like airplane travel or other crowded places,' noted Dowd.
While COVID levels are lower than previous summer waves, it is still a serious infection that can lead to death, complications and long COVID.
Do what you can to stay safe this summer, but 'with COVID prevention, don't let the perfect be the enemy of the good,' Dowd said.
'You don't have to do everything right, but even small precautions can add up to lower transmission and protect our communities,' she noted.
Related...
The Most Common COVID Symptoms Doctors Are Seeing This Summer
COVID Has Evolved, But Have COVID Tests? Experts Explain How Effective They Still Are
RFK Jr.'s Latest Move On Vaccines Is Going To Hurt EveryoneSolve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

A Trump-Biden Mind Meld on Price Controls
A Trump-Biden Mind Meld on Price Controls

Wall Street Journal

time24 minutes ago

  • Wall Street Journal

A Trump-Biden Mind Meld on Price Controls

Photo: Eric Thayer/Bloomberg News Your editorial 'The Political Race for Fewer Cures' (Aug. 6) identifies an ironclad rule of economics: Price controls create shortages. In this instance, restrictions on prescription drugs will lead to fewer cures. But there's another unintended consequence: Price controls will push down rebate payments to health plans. Those payments by drug makers are linked to list price—the higher the price, the higher the rebate payment. The sums allow patients to more easily access prescription drugs through lower out-of-pocket costs and reduced paperwork for doctors. Yet when the government artificially pushes down prices, they reduce rebate payments to health plans and their pharmacy benefit managers.

1 Beaten-Down Stock That Could Soar by the End of the Year
1 Beaten-Down Stock That Could Soar by the End of the Year

Yahoo

timean hour ago

  • Yahoo

1 Beaten-Down Stock That Could Soar by the End of the Year

Key Points Viking's leading weight management candidate is being investigated in two formulations. The stock could soar later this year, provided the oral version aces phase 2 studies. Viking Therapeutics is somewhat risky, but it also has significant upside potential. 10 stocks we like better than Viking Therapeutics › Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies. That's not exactly the strategy Viking Therapeutics (NASDAQ: VKTX) chose. The mid-cap biotech is working on weight loss therapies, an increasingly competitive market dominated by Eli Lilly (NYSE: LLY) and Novo Nordisk, as well as numerous other well-established players in the industry seeking to enter the space. Going up against these giants is no small challenge, but Viking is, so far, holding its own. And if it can play its cards right, its stock could soar by the end of the year and go on to generate strong returns from then on out. Here's more on Viking Therapeutics. Eli Lilly's setback creates an opportunity Viking Therapeutics' shares soared last year following the release of strong phase 2 data for its subcutaneous weight management candidate, VK2735. The stock has declined significantly since that milestone, although it's not due to anything Viking did wrong. Broader market volatility, combined with long-term shareholders taking some profits, is likely responsible for the stock's 40% drop over the trailing-12-month period. VK2735 is currently in phase 3 studies, but Viking is also developing an oral version of the medicine, which is in phase 2 clinical trials. There is a race to develop a highly effective oral GLP-1 anti-obesity therapy, since the current market leaders are administered via subcutaneous injection. If Viking Therapeutics' oral candidate can impress in mid-stage studies, the stock could soar. That's especially the case since Eli Lilly's investigational oral GLP-1 medicine, orforglipron, failed to perform as well as expected in a phase 3 study in obese or overweight patients who didn't have diabetes. Orforglipron led to a mean weight loss of 12.4% in a 72-week study, which wasn't as impressive as the market wanted. This result paled in comparison to Lilly's injectable Zepbound, which led to an average weight loss of 20.2% in a phase 3 study. Viking Therapeutics' shares jumped on the pharmaceutical giant's bad news, but there's plenty of upside left if its oral weight loss candidate meets Wall Street's expectations. It's best to start small Eli Lilly is perceived as the leader in the weight management market. The company's continued dominance in this field was likely somewhat baked into investor expectations, requiring it to deliver outstanding clinical trial results to justify its share price. Viking is a much smaller drugmaker than Lilly, so the market will likely have lower expectations for its data readouts for VK2735. Viking also has several other exciting candidates. The company is working on a drug called VK2809, a potential therapy for metabolic dysfunction-associated steatohepatitis (MASH), which produced solid results in phase 2 studies. There is a vast unmet need in MASH, considering several million people have the disease, yet the U.S. Food and Drug Administration has approved just a single medication for it. Elsewhere, Viking has a next-gen anti-obesity candidate that could soon start human clinical trials. The company has a lot going on, and if VK2735-related developments remain strong through the end of the year, the stock could soar. However, Viking -- like any clinical-stage biotech company -- is a somewhat risky bet. On the one hand, it has generated strong mid-stage data for two separate medicines that address high unmet needs. Its leading candidate, VK2735, has the potential to become a blockbuster; that's impressive. Even so, the stock will plummet if VK2735 encounters clinical setbacks. So, should you buy shares? In my view, it depends on your level of risk tolerance. Risk-averse investors should look elsewhere. If you're comfortable with a bit of volatility, you should seriously consider the stock; however, it would be wise to start by initiating a small position. If the data from the ongoing phase 2 study for oral VK2735 is good, it might be worth adding even more shares thereafter. Should you buy stock in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Beaten-Down Stock That Could Soar by the End of the Year was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store